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Introduction:  Angioedema is a rare potentially life threatening adverse effect of ACE inhibitor (ACEi) therapy possibly related to increased 
bradykinin levels. Angiotensin receptor blockers (ARBs) are known to elevate bradykinin by stimulation of the AT2 receptor. Whether by this 
mechanism ARBs increase the risk of angioedema is unknown.
Methods: A MEDLINE and COCHRANE database search identified all the prospective randomized controlled trials (RCTs) from 1960 to present 
dealing with the incidence of angioedema. The rate of angioedema per 100,000 person-years of follow up was compared separately for ACEi, ARBs 
and their controls. Effect estimates were pooled across studies using random-effects meta-analysis and heterogeneity was assessed using the I2 
statistics for comparison between ACEi and ARBs.
Results: A total of 20 RCTs with ACEi (488,175 person-years) and 12 RCTs with ARBs (184,267 person-years) were identified. The risk of 
angioedema was lower for diuretics (p=0.001), calcium channel blockers (CCBs) (p=0.003) and placebo (p=0.02) compared to ARBs. The risk of 
angioedema with ACEi was 2.2 times higher than with ARBs (p <0.0001) (95% CI 1.5 - 3.3).
Conclusion: The risk of angioedema with ARBs is less than half than that with ACE inhibitors. However, ARBs 
still confer a significantly higher risk of angioedema than do placebo and other antihypertensive drug classes.
